Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide in High-Risk Chronic Granulomatous Disease Patient with Invasive Mucormycosis.

Autor: Ruttens, D., Philippet, P., HSCT advisory team, Neven, Bénédicte, Lagrou, Katrien, Moshous, Despina, Bucciol, G., Meyts, I.
Předmět:
Zdroj: Journal of Clinical Immunology; Nov2023, Vol. 43 Issue 8, p1758-1765, 8p
Abstrakt: This document summarizes a letter published in the Journal of Clinical Immunology that discusses the successful case of an 11-year-old boy with chronic granulomatous disease (CGD) who underwent a haploidentical stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PTCy) after the failure of his first transplant. The patient had various complications related to CGD, including infections and inflammatory bowel disease. The haplo-HSCT with PTCy was successful, resulting in full donor chimerism and remission of the mucormycosis infection. The letter highlights the potential of this treatment option for CGD patients with severe infections. Additionally, the document provides a summary of several case studies involving HSCT for CGD patients, with varying outcomes but overall positive results. Another case study is reported, suggesting that a T-replete haploidentical HSCT can be a viable alternative treatment option for CGD patients with severe mucormycosis infections. The authors acknowledge the contributions of the HSCT advisory team and declare no conflicts of interest. The data from the study are available as electronic supplementary material. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: